Oxurion Receives Transparency Notification from Negma Group
Oxurion Receives Transparency Notification from Negma Group
Leuven, BELGIUM, Boston, MA, US – March 2, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:
Oxurion received a transparency notification on February 27, 2023 from Negma Group Ltd. indicating that as of February 20, 2023, it held 18,983,606 shares of the then outstanding 583,194,543 shares, and therefore crossed above the threshold (3%) by virtue of acquisition of voting securities. See Annex 1
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
For further information please contact:
| Oxurion NV Tom Graney Chief Executive Officer Tel: +32 16 75 13 10 " tom.graney@oxurion.com Michael Dillen Chief Business Officer Tel: +32 16 75 13 10 michael.dillen@oxurion.com | US Conway Communications Mary T. Conway mtconway@conwaycommsir.com ICR Westwicke Christopher Brinzey Tel: +1 617 835 9304 Chris.Brinzey@westwicke.com |
________
1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.
ANNEX 1
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
Attachments
- OXUR Transparency Notification (EN) 2023.3.2.FINAL
- OXUR Transparency Notification (NL) 2023.3.02.FINAL
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Resolutions from the annual shareholders’ meeting 202430.4.2024 18:02:02 CEST | Press release
Today an ordinary shareholders’ meeting was conducted. The following resolutions were made: • Approval of the audited Annual Report for 2023 • Approval of distribution of profit with payment of an ordinary dividend of DKK 2.00 or EUR 0.27 per A/B share of DKK 2 for the last four months (September 1 - December 31) of 2023. Legacy Novozymes shareholders will then have received a total pay-out of the 2023 adjusted net profit of DKK 6.20 per share, which equals an increase of 3% compared with 2022. • Approval of the Remuneration Report for 2023 • Approval of the remuneration of members of the Board of Directors • Re-election of Cornelis (Cees) de Jong as Chair and Jesper Brandgaard as Vice Chair of the Board of Directors • Re-election of Heine Dalsgaard, Sharon James, Kasim Kutay, Lise Kaae, Kevin Lane, Morten Sommer and Kim Stratton as members of the Board of Directors • Election of EY Godkendt Revisionspartnerselskab as the company’s auditors in respect of statutory financial and sustain
AMG Schedule for First Quarter 2024 Earnings Release30.4.2024 18:00:00 CEST | Press release
Amsterdam, 30 April 2024 --- AMG Critical Materials N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") will release its first quarter 2024 financial results on Tuesday, May 7, 2024, at approximately 18:00 CEST. AMG will host a conference call to discuss its financial results for the first quarter of 2024 at 09:00 CEST (08:00 BST / 3:00AM EDT) on Wednesday, May 8, 2024. Please connect approximately 10 minutes prior to the beginning of the call to ensure participation. The call-in information is as follows: Toll-free number: 1-888-632-3384 Alternate (toll) number: 1-785-424-1794 United Kingdom: 44 0800 048 7798 Netherlands: 31 0800 022 9530 When prompted for the conference ID, tell the operator AMGQ124 and you will be directed onto the call. The conference call will be available on the website www.amg-nv.com within twenty-four hours following completion of the call. About AMG AMG's mission is to provide critical materials and related process technologies to advance a less carbon-intensive world. To
Press Release: Annual General Meeting of April 30, 202430.4.2024 18:00:00 CEST | Press release
Annual General Meeting of April 30, 2024 Approval of the financial statements for the fiscal year 2023Distribution of a cash dividend of €3.76 per share, with payment as of May 15, 2024Board composition: renewal of two Directors and appointment of three new Independent Directors Paris, April 30, 2024. The Combined General Shareholders’ Meeting of Sanofi was held on April 30, 2024, under the chairmanship of Frédéric Oudéa. All resolutions submitted to the vote were adopted by the shareholders. The General Meeting approved the individual Company and consolidated financial statements for the fiscal year 2023 and decided on the distribution of an ordinary annual dividend of €3.76 per share. The payment of the dividend will be made on May 15, 2024. The General Meeting also renewed Rachel Duan and Lise Kingo as Directors, and approved the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy, all being qualified as independent Directors. On the proposal of the Appointments, Go
Changes in the management board of Northern Horizon Capital AS30.4.2024 17:40:00 CEST | Press release
Northern Horizon Capital AS, the management company of Baltic Horizon Fund, hereby informs of changes in the management board. Edvinas Karbauskas, a member of the management board of Northern Horizon Capital AS and co-fund manager of Baltic Horizon Fund since 3 January 2023, will resign from the management board, with his last date of office being 22 June 2024. He has been working in Northern Horizon Group since 2018. “On behalf of the Board, I would like to thank Edvinas for his contribution to Northern Horizon Capital group. In his various roles with the company, Edvinas has demonstrated an exceptional financial knowledge and a deep understanding of our sector coupled with a commitment to continuous improvement. Edvinas has contributed to shaping Baltic Horizon Fund’s strategic ambitions for the future, and I would like to express my sincere appreciation for his dedication”, comments Tarmo Karotam, fund manager of Baltic Horizon Fund. “After an extraordinary journey with Northern Hor
Treasury Bond Auction Announcement - RIKB 27 0415 - RIKS 37 011530.4.2024 17:31:00 CEST | Press release
SeriesRIKB 27 0415RIKS 37 0115ISINIS0000036291IS0000033793Maturity Date04/15/202701/15/2037Auction Date05/03/202405/03/2024Settlement Date05/08/202405/08/202410% addition05/07/202405/07/2024 On the Auction Date, between 10:30 am and 11:00 am, the Government Debt Management will auction Treasury bonds in the Series, with the ISIN numbers and with the Maturity Dates according to the table above. Payments for the Treasury bonds must be received by the Central Bank before 14:00 on the Settlement Date, and the Bonds will be delivered in electronic form on the same day. Article 6 of the General Terms of Auction for Treasury bonds applies for the right to purchase an additional 10%. Further reference is made to the description of the Treasury bond and the General Terms of Auction for Treasury bonds on the Government Debt Management website. For additional information please contact Tryggvi Freyr Harðarson, Government Debt Management, at +354 569 9630.